Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gardasil + CYD Dengue Vaccine
- Development stage
- Approved
- Lead developer
- Parent
- Modality
- Live Vector Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Subcutaneous
01
Overview
This drug entry refers to the concomitant or sequential administration of two distinct vaccines: the quadrivalent human papillomavirus (HPV) vaccine (Gardasil) and the tetravalent dengue vaccine (CYD-TDV, marketed as Dengvaxia). Gardasil is a recombinant vaccine composed of virus-like particles (VLPs) of the L1 protein from HPV types 6, 11, 16, and 18, designed to prevent cervical, vulvar, vaginal, and anal cancers, as well as genital warts. Dengvaxia is a live-attenuated tetravalent vaccine developed by Sanofi Pasteur using a yellow fever virus 17D backbone to express the pre-membrane and envelope proteins of the four dengue virus serotypes (DENV-1, 2, 3, and 4). The combination was evaluated in Phase 3 clinical trials to assess the safety and immunogenicity of co-administering these vaccines to adolescents, specifically to ensure that the immune response to one vaccine does not interfere with the other.
- Brand names
- Dengvaxia
- Other names
- Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, RecombinantTetravalent Dengue VaccineCYD-TDV + Gardasil
02
Targets
Dengue virus type 1 premembrane and envelope proteinsDengue virus type 2 pre-membrane and envelope proteinsDengue virus type 3 premembrane and envelope proteinsDengue virus type 4 precursor membrane and envelope proteinsHPV11 L1HPV (Human papillomavirus)HPV18 L1HPV6 L1 (Human papillomavirus type 6 major capsid protein L1)HPV16 (Human papillomavirus type 16)
Beyond the preview
Go deeper on Gardasil + CYD Dengue Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gardasil + CYD Dengue Vaccine.